Compare Ferrari NV (RACE) vs TransMedics Group Inc (TMDX) Price & Performance

Ferrari (RACE) trades at $389.91, up 0.91% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.15B and $1.60B in 2025, respectively. The company maintains high profitability margins and a robust balance sheet, though cash flow trends show recent volatility. Recent news highlights a share buyback program and strategic partnerships, supporting investor confidence.

The outlook for Ferrari remains positive due to consistent earnings beats, high margins, and analyst optimism, with a consensus price target of $462.75 implying 18.7% upside. Risks include valuation multiples above industry averages, competitive pressures in the luxury automotive sector, and macroeconomic sensitivity. Institutional buying activity and a dominant buy rating from analysts underscore long-term growth potential, but investors should monitor execution on future earnings and market sentiment shifts.

TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.

The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.